Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Dermacyd Silver Floral (Lactic Acid) - Acceptability.

Phase 3

Completed

Conditions: Hygiene

Interventions: Drug: LACTIC ACID(ND)

First Posted Date: 2009-07-07

Last Posted Date: 2010-09-14

Lead Sponsor: Sanofi

Target Recruit Count: 31

Registration Number: NCT00933569

Locations: 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil

Dermacyd PH_DESILSTY_FR (Lactic Acid) - Compatibility - Stay on Frutal

Phase 3

Completed

Conditions: Hygiene

Interventions: Drug: LACTIC ACID(ND)

First Posted Date: 2009-07-07

Last Posted Date: 2010-09-14

Lead Sponsor: Sanofi

Target Recruit Count: 55

Registration Number: NCT00933907

Locations: 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil

Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).

Phase 3

Completed

Conditions: Constipation

Interventions: Drug: SENNA+CASSIA(Naturetti)

First Posted Date: 2009-07-02

Last Posted Date: 2012-10-17

Lead Sponsor: Sanofi

Target Recruit Count: 117

Registration Number: NCT00931853

Locations: 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil

Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Lixisenatide (AVE0010)
Drug: Placebo

First Posted Date: 2009-07-02

Last Posted Date: 2012-02-23

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT00931372

Locations: 🇩🇪
Sanofi-Aventis Administrative Office, Berlin, Germany

KRYSTAL- KetopRofen lYsinate Sore ThroAt Lozenges

Phase 3

Completed

Conditions: Pain

Interventions: Drug: KETOPROFEN(RP19583)
Drug: Placebo

First Posted Date: 2009-06-30

Last Posted Date: 2010-05-18

Lead Sponsor: Sanofi

Target Recruit Count: 801

Registration Number: NCT00929877

Locations: 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain

A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Phase 1

Completed

Conditions: Solid Cancer

Interventions: Drug: cabazitaxel (XRP6258)

First Posted Date: 2009-06-22

Last Posted Date: 2013-05-16

Lead Sponsor: Sanofi

Target Recruit Count: 76

Registration Number: NCT00925743

Locations: 🇺🇸
Investigational Site Number 840002, Baltimore, Maryland, United States
🇺🇸
Investigational Site Number 840010, Decatur, Illinois, United States
🇺🇸
Investigational Site Number 840003, San Diego, California, United States

and more 4 locations